Randa



Indications and Reactions:

Role Indications Reactions
Primary
Cervix Carcinoma 71.4%
Gastric Cancer 28.6%
Enterocolitis 50.0%
Intestinal Perforation 33.3%
Vascular Injury 16.7%
Secondary
Hiv Infection 21.0%
Testis Cancer 11.4%
Bone Sarcoma 7.3%
Oesophageal Carcinoma 5.6%
Cervix Carcinoma 5.4%
Gastric Cancer 5.2%
Pineal Gland Cyst 5.2%
Chemotherapy 4.5%
Uterine Cancer 4.3%
Testicular Choriocarcinoma Stage Iii 3.9%
Testicular Neoplasm 3.6%
Pineal Neoplasm 3.4%
Small Cell Lung Cancer Stage Unspecified 3.4%
Prophylaxis Of Nausea And Vomiting 2.8%
Prophylaxis 2.4%
Gastric Ulcer 2.1%
Germ Cell Cancer 2.1%
Hyperlipidaemia 2.1%
Hyperuricaemia 2.1%
Hypothyroidism 2.1%
Interstitial Lung Disease 10.0%
Ventricular Tachycardia 10.0%
White Blood Cell Count Decreased 9.0%
Renal Impairment 8.0%
Pancreatitis Acute 6.0%
Respiratory Failure 6.0%
Deep Vein Thrombosis 5.0%
Pulmonary Fibrosis 5.0%
Stomatitis 5.0%
Liver Disorder 4.0%
Pancreatitis 4.0%
Pharyngeal Stenosis 4.0%
Renal Failure 4.0%
Azoospermia 3.0%
Bone Marrow Failure 3.0%
Leiomyosarcoma 3.0%
Palmar-plantar Erythrodysaesthesia Syndrome 3.0%
Shock 3.0%
Ventricular Fibrillation 3.0%
Acute Respiratory Failure 2.0%
Concomitant
Idiopathic Thrombocytopenic Purpura 22.8%
Immune Thrombocytopenic Purpura 17.3%
Prophylaxis 8.4%
Viith Nerve Paralysis 7.6%
Pleural Mesothelioma Malignant 6.0%
Malignant Mediastinal Neoplasm 4.3%
Gastric Cancer 3.5%
Cancer Pain 3.3%
Polyuria 3.0%
Lung Adenocarcinoma Stage Iv 2.7%
Premedication 2.4%
Analgesic Therapy 2.2%
Constipation 2.2%
Cough 2.2%
Diabetes Mellitus 2.2%
Infection Prophylaxis 2.2%
Malignant Neoplasm Of Renal Pelvis 2.2%
Metastatic Renal Cell Carcinoma 2.2%
Uterine Cancer 1.9%
Gastric Cancer Recurrent 1.6%
Neuroblastoma 13.1%
Pulmonary Embolism 8.2%
Renal Impairment 8.2%
White Blood Cell Count Decreased 8.2%
Pancytopenia 6.6%
Liver Disorder 4.9%
Platelet Count Increased 4.9%
Renal Failure 4.9%
Shock 4.9%
Hyponatraemia 3.3%
Inappropriate Antidiuretic Hormone Secretion 3.3%
Lung Neoplasm Malignant 3.3%
Malignant Neoplasm Progression 3.3%
Neoplasm Recurrence 3.3%
Oculomucocutaneous Syndrome 3.3%
Oedema Peripheral 3.3%
Pancreatitis Acute 3.3%
Platelet Count Decreased 3.3%
Pneumonia 3.3%
Pyrexia 3.3%